All In Biotech

NDA 050733 · Pfizer

Zithromax

Azithromycin · Injection

Discontinued

Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Jan 30, 1997

Approved uses

1

Original approval plus efficacy supplements

Registered trials

627

181 Phase 3, 43 recruiting

FAERS reports

19,146

13,050 serious, 1,467 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 9, 2026.

ZITHROMAX is a macrolide antibacterial drug indicated for the treatment of the following infections caused by designated susceptible microorganisms: • Community-acquired pneumonia in adults ( 1.1 ) • Pelvic inflammatory disease in adults ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZITHROMAX and other antibacterial drugs, ZITHROMAX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.3 ) 1.1 Community-Acquired Pneumonia ZITHROMAX is indicated for the treatment of adult patients with community-acquired pneumonia due to the following susceptible microorganisms: Chlamydophila pneumoniae , Haemophilus influenzae , Legionella pneumophila , Moraxella catarrhalis , Mycoplasma pneumoniae , Staphylococcus aureus , or Streptococcus pneumoniae in patients who require initial intravenous therapy. 1.2 Pelvic Inflammatory Disease ZITHROMAX is indicated for the treatment of adult patients with pelvic inflammatory disease due to the following susceptible microorganisms: Chlamydia trachomatis , Neisseria gonorrhoeae , or Mycoplasma hominis in patients who require initial intravenous therapy. If anaerobic microorganisms are suspected of contributing to the infection, an antimicrobial agent with anaerobic activity should be administered in combination with ZITHROMAX. 1.3 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZITHROMAX and other antibacterial drugs, ZITHROMAX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial...

Mechanism: Azithromycin is a macrolide antibacterial drug. [see Microbiology (12.4) ] Mechanism of Action Azithromycin acts by binding to the 23S rRNA of the 50S ribosomal subunit of susceptible microorganisms inhibiting bacterial protein synthesis and impeding the assembly of the 50S ribosomal subunit.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ZITHROMAX · AZITHROMYCIN EQ 500MG BASE/VIAL · INJECTABLE, INJECTION · Discontinued · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Azithromycin" as an intervention, any sponsor and status, largest first.

All 627 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug hypersensitivity1,997
  • dyspnoea1,466
  • drug ineffective1,199
  • nausea1,133
  • pain1,088
  • diarrhoea1,040
  • off label use1,014
  • fatigue1,013
  • pneumonia990
  • headache951
  • cough917
  • anxiety883

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004585
2005655
2006627
2007381
2008456
2009562
2010951
2011927
20121,059
2013740
2014905
20151,130
20161,333
20171,066
20181,335
20191,273
20201,191
2021904
2022774
2023716
2024639
2025545
2026392

Recalls

1 FDA enforcement reports for this application.

  • Jan 2, 2014 · Class III · Terminated

    Failed Impurities/Degradation Specifications: Pfizer is recalling certain lots due to out of specification results for azithromycin N-oxide degradant.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Jan 20, 2026

    Zithromax IV, Injection, 500 mg/5 mL (NDC 0069-3150-83). Discontinuation of the manufacture of the drug.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zithromax* (Azithromycin)

2024 spending

$20K

Beneficiaries

708

1,040 claims

Per beneficiary

$29

$2.43 per unit

View as table
YearSpending
2020$50,470
2021$33,893
2022$26,479
2023$25,423
2024$20,386

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,833 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.